GLP-1 and surgery: when to pause Wegovy, Zepbound, and Ozempic

You arrive at the endoscopy suite at 6:45 a.m. for a screening colonoscopy you've been putting off for two years. You're hungry, you're cold under the thin gown, and you just want this over with. The intake nurse runs through the questionnaire and pauses at the medication list. "You're on Wegovy? When was your last shot?" Tuesday night, you say. Three days ago. She steps out, comes back with the anesthesiologist, and the next sentence is the one nobody on this side of a 7 a.m. NPO wants to hear: we're going to have to reschedule.

This scene plays out every week now in surgical centers from Houston to Manchester to Sydney. Roughly one in eight US adults has tried a GLP-1, a big slice of the elective-procedure calendar now belongs to people on weekly semaglutide and tirzepatide, and the anesthesia community spent 2023, 2024, and 2025 hammering out what to do about it. Short version: weekly injections come off for at least seven days before sedation. Daily formulations come off the morning of. The reason is mechanical, not theoretical — and the worst-case version of "we didn't pause" is aspiration pneumonitis on the OR table.

What follows: the pharmacology that drives the rule, the exact pause windows by drug as of April 2026, what counts as "a procedure that needs the pause," the brand mapping if your patient or partner is overseas, and the questions that save you a second appointment with your surgical team. US-default, with notes for readers in the UK, EU, Australia, Canada, Singapore, and Dubai who run into different brand names at the pharmacy counter.

Why GLP-1s force a pause in the first place

GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide, dulaglutide, the new oral orforglipron — slow gastric emptying. It's the same mechanism that makes Wegovy and Zepbound work for weight loss. Food sits longer. Hunger arrives later. The brain's "I'm full" signal lands earlier. All of that is the point at the dinner table. At the head of an OR bed, it's a liability.

What set off the alarm in 2023 was Lilly's own pharmacology data on tirzepatide, showing roughly 70% delay in gastric emptying at peak plasma concentration. Semaglutide's effect is smaller, but it's real. Picture it in practice: someone who fasted from midnight, gave up clear liquids at 4 a.m., and walked into the suite at 7 a.m. can still carry a partly full stomach when the anesthesiologist pushes propofol. Once the airway reflexes drop, gastric contents can flow up. If they reach the lungs, you get chemical pneumonitis — a serious, sometimes ICU-level complication.

The aspiration signal isn't huge, but it isn't zero either. A large retrospective cohort published in Gastroenterology in 2024 found a post-endoscopy aspiration-pneumonia rate of about 0.83% in GLP-1 users versus about 0.63% in matched non-users — a hazard ratio of roughly 1.33 (95% CI 1.02–1.74), and higher still for propofol sedation. Retrospective and far from definitive, sure, but the direction held steady enough that the American Society of Anesthesiologists issued its first formal consensus statement in June 2023 recommending a pre-op hold. Multisociety guidance updated in 2024 and 2025 — work involving the AGA, ASMBS, IFSO, and SAGES — refined the timing, and it's the kind of document your surgical team is most likely working from in 2026.

The cleanest framing I've heard from a perioperative colleague: the medication isn't the problem; the medication's effect on the stomach at induction is the problem. Pause the medication, and the stomach behaves like a normal NPO stomach by morning. Don't pause it, and your anesthesiologist is doing a full-stomach induction whether you knew it or not.

Pause windows by drug

This is the table to screenshot before your next pre-op appointment. Multi-society consensus as of April 2026, anchored by the October 2024 multisociety statement (ASA, AGA, ASMBS, IFSO, SAGES) and later 2025 updates, and consistent with ESAIC, the Royal College of Anaesthetists, JSA, KSA, CSA, and the HK College of Anaesthesiologists.

The half-lives behind those numbers: semaglutide sits around 7 days, tirzepatide around 5 days, dulaglutide around 5 days, liraglutide around 13 hours, orforglipron around 24 hours. The seven-day rule for weekly injections is roughly one half-life, which gets you to about half-concentration at induction — the level where the gastric-emptying effect drops back toward unmedicated baseline. Not a full washout. Five half-lives — the textbook clearance window — would mean 35 days for semaglutide, and nobody is asking you to do that for a routine colonoscopy.

The standard ASA NPO baseline still applies on top of the GLP-1 hold: 2 hours for clear liquids, 6 hours for a light meal, 8 hours for a heavy or fatty meal. For GLP-1 users, many anesthesia teams now extend the solid-food window beyond 8 hours, or add a gastric ultrasound at induction to confirm the stomach is empty. If you arrive having held your weekly shot for 7 days and fasted overnight, and the gastric ultrasound still shows a full antrum, the team will either delay the case or convert to a rapid-sequence induction with airway protection.

What counts as "a procedure that needs the pause"

The umbrella is wider than most patients expect. The pause applies to anything that will dial down your protective airway reflexes — not just to what feels like "real surgery."

• General anesthesia. Any procedure where you'll be intubated or have a laryngeal mask airway placed.
• Deep sedation. Colonoscopy and gastroscopy with propofol. The biggest single category for GLP-1 cases in 2026.
• Moderate sedation (MAC). Cosmetic procedures, dental sedation, IVF egg retrieval, cardiac catheterization.
• Bariatric surgery. Sleeve gastrectomy, gastric bypass, revisional procedures. Pause is mandatory; many centers extend it.
• Cosmetic surgery under sedation. Liposuction, abdominoplasty, breast procedures, facial work.
• Dental sedation. Wisdom-tooth extractions, full-mouth restorations under IV sedation. The category most often missed because patients don't think of the dentist as "surgery."
• Endoscopic ultrasound, ERCP, bronchoscopy. All standard.

What does not require the GLP-1 hold: local anesthesia without sedation. A skin biopsy under lidocaine, a routine dermatology excision, a cataract block, most dental fillings — your stomach isn't the issue because your airway reflexes stay online. Confirm with the proceduralist; don't assume.

The genuinely hard category is emergency surgery. If you're going to the OR for an appendix or a fracture and you took your weekly Wegovy 36 hours ago, don't delay the surgery. Tell the anesthesia team. They'll use full-stomach precautions — rapid-sequence induction, cricoid pressure as judged, gastric ultrasound, sometimes a nasogastric tube before induction. The risk math on a delayed appendectomy is worse than the aspiration risk on a properly managed full-stomach induction.

The brand-by-market reality

If you're in the US and staying put, "Wegovy and Zepbound" covers most of the conversation. The moment a friend, a parent, or a patient is filling a pen overseas, the brand names splinter in ways that trip up pre-op questionnaires. Here's the map.

Western markets:

Asian markets:

Three brand-mapping traps worth flagging on a pre-op questionnaire:

• Tirzepatide brand split. The US is the only major market that splits Mounjaro (T2D label) from Zepbound (obesity label). Everywhere else, Mounjaro is the only brand. Korea's MFDS approved Mounjaro for obesity in July 2024 (though it's not insurance-covered). Japan splits the molecule the way the US does: マンジャロ carries the T2D label, and the obesity indication is approved under a separate brand, ゼップバウンド (Zepbound, approved December 2024). The pause rule doesn't care about indication or brand; it cares about the molecule.
• Wegovy under different names. Wegovy in the US, UK, EU, KSA, and UAE. 위고비 in Korea. ウゴービ in Japan. 诺和盈 in mainland China. 週纖達 in Taiwan. Same semaglutide 2.4 mg molecule. Same 7-day pause.
• Foundayo is US-only as of April 2026. Approved by the FDA on April 1, 2026. Not yet approved by the EMA, MHRA, MFDS, PMDA, NMPA, TFDA, SFDA, or MOHAP. If a patient says they're on a "GLP-1 pill" and you're not in the US, double-check whether they mean Rybelsus (oral semaglutide) or compounded supply.

Globally the picture is convergent: nine of ten major regional anesthesia societies endorsed a 1-week hold for weekly preparations by the end of 2025. SFDA in Saudi Arabia and MOHAP in the UAE haven't issued separate hold guidance, so most centers there default to the ASA position. Traveling for elective surgery? Ask the operating team's lead anesthesiologist, point blank, which guideline they're working from.

The local healthcare reality (US)

Knowing the rule is half the work. Bending it around a US insurance and refill calendar is the other half. A few patterns come up over and over.

Telehealth refill timing. If you fill Wegovy or Zepbound through Ro, Hims, Henry Meds, LillyDirect, or NovoCare, the pen ships on a fixed cadence. The clinic doesn't know your colonoscopy is on a Tuesday. A pen shipped to arrive Friday is one you might inject Sunday — three days before your Wednesday procedure — purely on autopilot. The fix is unromantic: open the patient portal, push the next ship date, message the clinic with your procedure date. Do this 10 to 14 days out, not 48 hours out, because the pharmacy queue isn't always nimble.

The prior-authorization dance. Most commercial plans require a PA for Wegovy and Zepbound. If you skip a dose for a procedure and your PA renewal lands in the same window, you can end up with a refill hold right when you're trying to restart. Ask your endocrinologist or weight-loss clinic to write the resume date into the chart so a denial appeal has documentation.

Dental sedation surprise. This is the scenario people miss most in 2026. Nobody files "wisdom teeth out" under places-where-my-Wegovy-matters. It belongs there. An oral surgeon running IV moderate sedation is switching off the same airway reflexes the GI suite switches off. The multisociety perioperative guidance covers procedural sedation outright, dental sedation included. If your wisdom-tooth extraction is Friday and you took Wegovy on Tuesday, that's three days, not seven, and the responsible move is to reschedule. The dentist will sigh. Reschedule anyway.

Medicare and the obesity-coverage shift. As of April 2026, Medicare coverage for Wegovy applies through the cardiovascular indication; broader anti-obesity coverage is in flux. If you're 65+ and on Wegovy through the CV pathway, the pause math doesn't change — but the cost of a missed pen due to scheduling can. Confirm refill rules with your Part D plan before you reschedule a procedure.

For UK readers on the NHS, the Royal College of Anaesthetists endorsed the ASA stance in 2024 and most NHS trusts work to the same 7-day rule. Australian patients on PBS-listed Mounjaro should expect the same conversation; the Australian and New Zealand College of Anaesthetists aligned in 2024. Singapore's HSA and Dubai's DHA largely follow ASA.

Questions to bring to your surgical team

Print this list, or copy it into your pre-op portal message. The ones that save you the rescheduled morning.

• "I'm on [specific brand and dose]. My last injection was [date and time]. Is that the right pause for the procedure I'm scheduled for?"
• "Will the team be using gastric ultrasound at induction? If yes, what's the threshold for delaying the case?"
• "If I can't safely hold for the full 7 days — for example, if I'm a T2D patient using semaglutide for glycemic control — what's the bridging plan?"
• "How long after the procedure can I resume the GLP-1?" Most teams clear a resume the next day for routine cases; bariatric and major abdominal cases extend that.
• "Will the procedure or the anesthesia change my titration schedule?" If you're climbing toward 2.4 mg Wegovy or 15 mg Zepbound, missing a week sometimes means restarting at a lower step. Confirm.
• "If I get nauseous at home before the procedure, is that a reason to call you, or is it expected?" Especially if you escalated the dose recently.
• "Are there any other meds I should also hold?" Metformin, SGLT2 inhibitors, blood thinners, and ACE inhibitors all have their own pre-op rules; lump them into one conversation.

If you're being seen by a surgical team that hasn't asked about GLP-1s, mention it anyway. The multisociety perioperative guidance is the standard, but rollout is uneven — small ambulatory centers and dental practices are still catching up.

One perioperative nurse I trust phrased it like this: the patient who volunteers their GLP-1 at intake gets a calm rescheduling call; the patient who doesn't gets a same-morning cancellation with a hungry stomach and a wasted PTO day. The first conversation is always cheaper than the second.

What to ask the pharmacist before your refill

Ten minutes at the pharmacy counter beats a rescheduled procedure.

• "When is my next pen scheduled to ship?" If you order through a manufacturer DTC like LillyDirect or NovoCare, the ship date is the variable, not the pickup date.
• "Can we push the refill so I don't get a fresh pen the same week as my surgery?" Most pharmacists can adjust by 7 to 14 days without a new prescription.
• "If I miss a weekly dose, what's the resume rule?" The official answers differ by molecule: for semaglutide (Ozempic, Wegovy), if it's been less than 5 days, take the missed dose, otherwise skip and resume on your usual day. For tirzepatide (Mounjaro, Zepbound), the label window is 4 days (96 hours), not 5. When in doubt, follow the product label.
• "Will skipping affect my insurance coverage?" Some PBMs flag adherence gaps. A documented procedural reason in the chart is your protection.
• "If I'm escalating doses, does a missed week reset the titration?" For Wegovy (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) and Zepbound (2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg), the answer depends on how long you'd been on the current dose and your prescriber's protocol.

Compounded tirzepatide and semaglutide are a separate conversation. The 2024 FDA shortage status changed in 2025, and supply through 503A and 503B pharmacies has tightened. If you're on compounded supply, the pause window is the same, but resume access can be less predictable.

What to do if you cannot hold

For someone using Ozempic, Mounjaro, or Trulicity for type 2 diabetes — not for weight — the pause conversation gets more delicate. The 7-day hold pulls one of your glycemic tools off the board for a week. Some patients sail through that; others, especially anyone whose A1c sits close to target threshold, don't.

Your endocrinologist can pick from three workable approaches:

• Accept the pause with monitoring. For most T2D patients, holding one weekly dose and checking fingerstick glucose more often is enough. Hyperglycemia at induction is generally easier to manage acutely than aspiration.
• Bridge with basal insulin or short-acting insulin. For patients at higher A1c or with stricter targets, a brief insulin bridge across the pause week is standard. This is a prescription change, not a DIY adjustment.
• Selective non-pause for low-risk procedures. If the procedure is brief, the airway risk is low (a peripheral block under light sedation, for example), and the patient is at meaningful glycemic risk, some anesthesia teams will proceed with the GLP-1 on board plus a gastric ultrasound at induction. This is a case-by-case call between your endocrinologist and your anesthesiologist — not a default.

For patients on a GLP-1 plus insulin or a sulfonylurea (glimepiride, glipizide, glyburide), the pause week also raises the risk of insulin-driven hypoglycemia if doses aren't adjusted. The endocrinologist usually trims the basal slightly for the holding week — not a step you'd manage alone.

If you're genuinely uncertain whether you can safely hold, that's the conversation to have at your pre-op visit, not at 6 a.m. on procedure day with an IV in your arm and your phone on airplane mode.

The realistic take

As far as recent medical guidance goes, the pause-before-surgery rule on GLP-1s is one of the cleaner ones. The pharmacology is mechanical, the timing is concrete, and the downside of getting it wrong — chemical pneumonitis from aspiration — is grim enough that the major regional anesthesia societies converged fast on a single rule. Hold the weekly shot for at least 7 days. Hold the daily formulation the morning of. Tell your surgical and dental teams what you're on, in brand and dose. And push your refill so a fresh pen doesn't land the same week as your sedation.

If you're reading this with a procedure already on the calendar, the to-do list is short. Count back 7 days from the procedure date, mark that as your last allowed weekly dose, and message your surgical team and your prescribing clinic. Five minutes of admin now buys back the morning where you'd otherwise show up fasting and gowned at 6:45 a.m. and get sent home hungry. And if your medication list carries anything trickier — diabetes management, a recent dose escalation, a compounded supply — that's the thread to pull at your pre-op visit, while there's still room to adjust the plan.

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. All GLP-1 medications discussed are prescription drugs — do not start, stop, or change any medication without consulting your doctor. Individual results vary. For the most current prescribing information, refer to the FDA-approved labeling for each drug.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app